-
Je něco špatně v tomto záznamu ?
Inhibition of PHLDA3 expression in human superoxide dismutase 1-mutant amyotrophic lateral sclerosis astrocytes protects against neurotoxicity
K. Szebényi, I. Vargová, V. Petrova, J. Turečková, GM. Gibbons, M. Řehořová, M. Abdelgawad, A. Sándor, D. Marekova, JCF. Kwok, P. Jendelová, JW. Fawcett, A. Lakatos
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2019
PubMed Central
od 2019
Oxford Journals Open Access Collection
od 2019-07-01
ROAD: Directory of Open Access Scholarly Resources
od 2019
- Publikační typ
- časopisecké články MeSH
Pleckstrin homology-like domain family A-member 3 (PHLDA3) has recently been identified as a player in adaptive and maladaptive cellular stress pathways. The outcome of pleckstrin homology-like domain family A-member 3 signalling was shown to vary across different cell types and states. It emerges that its expression and protein level are highly increased in amyotrophic lateral sclerosis (ALS) patient-derived astrocytes. Whether it orchestrates a supportive or detrimental function remains unexplored in the context of neurodegenerative pathologies. To directly address the role of pleckstrin homology-like domain family A-member 3 in healthy and ALS astrocytes, we used overexpression and knockdown strategies. We generated cultures of primary mouse astrocytes and also human astrocytes from control and ALS patient-derived induced pluripotent stem cells harbouring the superoxide dismutase 1 mutation. Then, we assessed astrocyte viability and the impact of their secretome on oxidative stress responses in human stem cell-derived cortical and spinal neuronal cultures. Here, we show that PHLDA3 overexpression or knockdown in control astrocytes does not significantly affect astrocyte viability or reactive oxygen species production. However, PHLDA3 knockdown in ALS astrocytes diminishes reactive oxygen species concentrations in their supernatants, indicating that pleckstrin homology-like domain family A-member 3 can facilitate stress responses in cells with altered homeostasis. In support, supernatants of PHLDA3-silenced ALS and even control spinal astrocytes with a lower pleckstrin homology-like domain family A-member 3 protein content could prevent sodium arsenite-induced stress granule formation in spinal neurons. Our findings provide evidence that reducing pleckstrin homology-like domain family A-member 3 levels may transform astrocytes into a more neurosupportive state relevant to targeting non-cell autonomous ALS pathology.
2nd Faculty of Medicine Charles University Prague 150 06 Czech Republic
Doctoral School of Molecular Medicine Semmelweis University Budapest 1085 Hungary
Institute of Experimental Medicine Czech Academy of Sciences Prague 142 20 Czech Republic
MRC WT Cambridge Stem Cell Institute Biomedical Campus Cambridge CB2 0AW UK
Research Centre of Natural Sciences Institute of Molecular Life Sciences Budapest 1117 Hungary
School of Biological Sciences University of Leeds Leeds LS2 9JT UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018160
- 003
- CZ-PrNML
- 005
- 20241016081808.0
- 007
- ta
- 008
- 241008s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/braincomms/fcae244 $2 doi
- 035 __
- $a (PubMed)39144751
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Szebényi, Kornélia $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, CB2 0PY, UK $u Research Centre of Natural Sciences, Institute of Molecular Life Sciences, Budapest, 1117, Hungary
- 245 10
- $a Inhibition of PHLDA3 expression in human superoxide dismutase 1-mutant amyotrophic lateral sclerosis astrocytes protects against neurotoxicity / $c K. Szebényi, I. Vargová, V. Petrova, J. Turečková, GM. Gibbons, M. Řehořová, M. Abdelgawad, A. Sándor, D. Marekova, JCF. Kwok, P. Jendelová, JW. Fawcett, A. Lakatos
- 520 9_
- $a Pleckstrin homology-like domain family A-member 3 (PHLDA3) has recently been identified as a player in adaptive and maladaptive cellular stress pathways. The outcome of pleckstrin homology-like domain family A-member 3 signalling was shown to vary across different cell types and states. It emerges that its expression and protein level are highly increased in amyotrophic lateral sclerosis (ALS) patient-derived astrocytes. Whether it orchestrates a supportive or detrimental function remains unexplored in the context of neurodegenerative pathologies. To directly address the role of pleckstrin homology-like domain family A-member 3 in healthy and ALS astrocytes, we used overexpression and knockdown strategies. We generated cultures of primary mouse astrocytes and also human astrocytes from control and ALS patient-derived induced pluripotent stem cells harbouring the superoxide dismutase 1 mutation. Then, we assessed astrocyte viability and the impact of their secretome on oxidative stress responses in human stem cell-derived cortical and spinal neuronal cultures. Here, we show that PHLDA3 overexpression or knockdown in control astrocytes does not significantly affect astrocyte viability or reactive oxygen species production. However, PHLDA3 knockdown in ALS astrocytes diminishes reactive oxygen species concentrations in their supernatants, indicating that pleckstrin homology-like domain family A-member 3 can facilitate stress responses in cells with altered homeostasis. In support, supernatants of PHLDA3-silenced ALS and even control spinal astrocytes with a lower pleckstrin homology-like domain family A-member 3 protein content could prevent sodium arsenite-induced stress granule formation in spinal neurons. Our findings provide evidence that reducing pleckstrin homology-like domain family A-member 3 levels may transform astrocytes into a more neurosupportive state relevant to targeting non-cell autonomous ALS pathology.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vargová, Ingrid $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, 142 20, Czech Republic
- 700 1_
- $a Petrova, Veselina $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, CB2 0PY, UK $1 https://orcid.org/0000000255930198
- 700 1_
- $a Turečková, Jana $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, 142 20, Czech Republic
- 700 1_
- $a Gibbons, George M $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, CB2 0PY, UK
- 700 1_
- $a Řehořová, Monika $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, 142 20, Czech Republic $u Second Faculty of Medicine, Charles University, Prague, 150 06, Czech Republic
- 700 1_
- $a Abdelgawad, Mai $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, CB2 0PY, UK
- 700 1_
- $a Sándor, Alexandra $u Research Centre of Natural Sciences, Institute of Molecular Life Sciences, Budapest, 1117, Hungary $u Doctoral School of Molecular Medicine, Semmelweis University, Budapest, 1085, Hungary
- 700 1_
- $a Marekova, Dana $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, 142 20, Czech Republic
- 700 1_
- $a Kwok, Jessica C F $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, 142 20, Czech Republic $u School of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK
- 700 1_
- $a Jendelová, Pavla $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, 142 20, Czech Republic $u Second Faculty of Medicine, Charles University, Prague, 150 06, Czech Republic
- 700 1_
- $a Fawcett, James W $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, CB2 0PY, UK $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, 142 20, Czech Republic
- 700 1_
- $a Lakatos, András $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, CB2 0PY, UK $u MRC-WT Cambridge Stem Cell Institute, Biomedical Campus, Cambridge, CB2 0AW, UK
- 773 0_
- $w MED00205536 $t Brain communications $x 2632-1297 $g Roč. 6, č. 4 (2024), s. fcae244
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39144751 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016081803 $b ABA008
- 999 __
- $a ok $b bmc $g 2196479 $s 1230111
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 6 $c 4 $d fcae244 $e 20240725 $i 2632-1297 $m Brain communications $n Brain Commun $x MED00205536
- LZP __
- $a Pubmed-20241008